Mariner
AVDL

Mariner’s Avadel Pharmaceuticals AVDL Stock Holding History

Mariner’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-38,861
Closed -$381K – 1155
2021
Q3 		$381K Buy
38,861
+7,732
+25% +$60.9K ﹤0.01% 895
2021
Q2 		$209K Hold
31,129
– – ﹤0.01% 907
2021
Q1 		$281K Hold
31,129
– – ﹤0.01% 819
2020
Q4 		$208K Buy
+31,129
New +$195K ﹤0.01% 778

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Mariner's AVDL Position: Q4 2021 in Review

Mariner sold out of Avadel Pharmaceuticals (AVDL) in Q4 2021, closing a stake of 38,861 shares — an estimated $381K sold.

Mariner first reported a position in AVDL in Q4 2020 and held it in 4 quarters. The position peaked at $381K in Q3 2021. 83 funds tracked by Wall St. Rank hold AVDL as of Q4 2021.

  • Mariner reported no remaining Avadel Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Mariner sold 38,861 Avadel Pharmaceuticals shares in Q4 2021, an estimated $381K.
  • Mariner first reported a position in Avadel Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Mariner's Avadel Pharmaceuticals position peaked at $381K in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2021.

Based on Mariner's 13F filing for Q4 2021, filed 14 Feb 2022.